Subtype-specific therapy for DLBCL: are we there yet?
- PMID: 26472733
- DOI: 10.1182/blood-2015-08-662510
Subtype-specific therapy for DLBCL: are we there yet?
Abstract
In this issue of Blood, Offner et al report the results of LYM-2034, a phase 2 multinational trial in which 164 patients with nongerminal center B-cell–like diffuse large B-cell lymphoma (non-GCB DLBCL) were randomized to receive rituximab, cyclophosphamide, adriamycin, prednisone, and either vincristine (R-CHOP) or bortezomib (VR-CAP). DLBCL, previously recognized as a single disease entity, represents a heterogeneous group of diseases.
Comment on
- 
  
  Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.Blood. 2015 Oct 15;126(16):1893-901. doi: 10.1182/blood-2015-03-632430. Epub 2015 Jul 31. Blood. 2015. PMID: 26232170 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Research Materials
- Miscellaneous
 
        
